Residency · Residency · Plastic Surgery

Gynecomastia: Evaluation and Surgical Treatment

Introduction

Gynecomastia is benign enlargement of the male breast due to proliferation of glandular tissue. Most common breast condition in males. Prevalence: up to 65% of men at some point in life. Distinguished from pseudogynecomastia (adipose tissue without glandular proliferation). Significant psychosocial impact; affects self-esteem and quality of life.

Etiology

Physiologic Gynecomastia

Neonatal: maternal/placental estrogen transfer; resolves in weeks. Pubertal: peaks at age 13-14; 60-70% of adolescent males; usually resolves within 2 years. Senescent: age 50-80; declining testosterone with relative estrogen excess.

Pathologic Causes

Hormonal imbalance: any condition increasing estrogen or decreasing androgen activity. Medications (most common pathologic cause): Antiandrogens: spironolactone, flutamide, finasteride, bicalutamide. Estrogens/estrogen-like: diethylstilbestrol, digitalis, phytoestrogens. Cimetidine, omeprazole. Ketoconazole. Marijuana, alcohol, heroin, amphetamines. Anabolic steroids.

Chemotherapy (alkylating agents). Antiretrovirals (efavirenz). Psychiatric medications: haloperidol, risperidone, tricyclics. Endocrine: Hypogonadism (Klinefelter syndrome 47,XXY — most common genetic cause). Hyperthyroidism. Adrenal tumors (estrogen-secreting). Testicular tumors (Leydig cell, Sertoli cell, germ cell with HCG production).

Liver disease: impaired estrogen metabolism; increased sex hormone-binding globulin (SHBG). Renal failure: decreased testosterone clearance, elevated LH/FSH. Obesity: increased aromatase activity (conversion of androgens to estrogens in adipose tissue). Idiopathic: 25% of cases have no identifiable cause.

Pathophysiology

Results from imbalance between estrogen (stimulatory) and androgen (inhibitory) effects on breast tissue. Estrogen promotes ductal and stromal proliferation. Androgens inhibit breast tissue growth. Any condition that increases the estrogen-to-androgen ratio can cause gynecomastia. Aromatase enzyme (CYP19A1) in peripheral adipose tissue converts testosterone/androstenedione to estradiol/estrone.

Classification

Simon Classification

Grade I: minor breast enlargement without skin excess. Grade IIa: moderate enlargement without skin excess. Grade IIb: moderate enlargement with minor skin excess. Grade III: severe enlargement with significant skin excess (mimics female breast ptosis).

Rohrich Classification (Based on Treatment)

Grade I: minimal hypertrophy (<250g), no ptosis. Grade II: moderate hypertrophy (250-500g), no ptosis. Grade III: severe hypertrophy (>500g), Grade I ptosis. Grade IV: severe hypertrophy with Grade II-III ptosis.

Evaluation

History

Duration and progression. Pain or tenderness (suggests active proliferative phase). Medication review (thorough drug history is essential). Substance use: marijuana, alcohol, anabolic steroids.

Symptoms of hypogonadism: decreased libido, erectile dysfunction, fatigue. Symptoms of hyperthyroidism, liver disease, renal disease. Testicular symptoms: mass, pain, changes in size. Family history.

Physical Examination

Distinguish glandular tissue (firm, rubbery, subareolar disc) from adipose tissue (soft, diffuse). Measure breast dimensions. Assess for skin excess and ptosis. Testicular exam: size, masses, atrophy.

Signs of liver disease, thyroid disease, hypogonadism. Rule out male breast cancer: hard, eccentric mass, skin fixation, nipple discharge, axillary lymphadenopathy.

Laboratory Workup

Initial panel: testosterone (total and free), estradiol, LH, FSH, beta-HCG, liver function tests, thyroid function tests, renal function. If beta-HCG elevated: testicular ultrasound, CT abdomen/chest (germ cell tumor). If estradiol elevated: testicular ultrasound, adrenal imaging. If testosterone low/LH-FSH elevated: karyotype (Klinefelter).

If testosterone low/LH-FSH low: pituitary MRI (hypogonadotropic hypogonadism). Mammography/ultrasound if breast cancer suspected (unilateral, hard, eccentric mass, bloody nipple discharge).

Medical Management

Observation: appropriate for pubertal gynecomastia (most resolves spontaneously within 2 years). Address underlying cause: discontinue offending medications, treat endocrine disorders. Tamoxifen (selective estrogen receptor modulator): 10-20 mg daily for 3-6 months. Most effective in early proliferative phase (pain/tenderness present).

80-90% response in early disease; less effective with long-standing fibrotic tissue. Raloxifene: alternative SERM; similar efficacy. Aromatase inhibitors (anastrozole, letrozole): reduce peripheral estrogen production. Less evidence than tamoxifen; used in pubertal gynecomastia refractory to observation.

Danazol: synthetic androgen; limited use due to side effects. Medical therapy is most effective when tissue is glandular (proliferative); once fibrotic, surgery is required.

Surgical Treatment

Indications

Gynecomastia persisting >12-24 months (fibrotic phase; unlikely to resolve medically). Failed medical therapy. Significant psychosocial distress. Severe grade with skin excess.

Liposuction-Assisted Excision (Most Common Approach)

Technique

Liposuction (UAL/VASER or PAL preferred) to remove adipose tissue and define chest contour. Small periareolar (inferior semicircular) incision for direct glandular excision. Subcutaneous glandular tissue excised sharply, preserving a thin layer of tissue under the NAC to prevent crater deformity. Specimen sent to pathology. Feathering of the transition zones for smooth contour.

Advantages

Minimal scarring (small periareolar incision + liposuction cannula sites). Addresses both glandular and adipose components. Good contour results in Grade I-IIb.

Direct Excision (Pull-Through Technique)

Periareolar incision; glandular tissue excised directly. Used when liposuction is insufficient or unavailable. Risk of NAC depression or saucer deformity if too aggressive.

Skin Excision Techniques (Grade III/IV)

Circumareolar (Periareolar)

For moderate skin excess. Concentric skin excision around the areola. Purse-string closure reduces skin envelope. Risk: areolar widening, irregular scarring, limited excision capacity.

Inferior Pedicle Reduction (Wise Pattern)

For severe gynecomastia with significant ptosis. Same technique as female breast reduction. NAC transposed on inferior pedicle. Inverted-T scar. Indicated for massive gynecomastia.

Free Nipple Graft

For the most severe cases with extreme ptosis and excess skin. NAC removed, tissue excised, skin resected, NAC grafted to new position. Ensures viability when pedicle length would be unsafe.

<image>Surgical illustration showing liposuction-assisted excision for gynecomastia treatment. The left panel shows an anterior view of a male chest with Grade IIa gynecomastia with the areas to be treated by liposuction marked with crosshatched lines and the periareolar incision site marked with a dashed semicircle. The center panel shows an intraoperative view through the periareolar incision with a retractor exposing the firm glandular disc being excised with electrocautery, while a thin layer of subcutaneous fat is preserved superficial to the pectoralis fascia to prevent cratering. The right panel shows the postoperative result with a flat masculine chest contour, the minimal periareolar scar, and the small liposuction port sites. Labels identify the glandular tissue, preserved fat layer, pectoralis major fascia, and the excised specimen.</image>

Postoperative Care

Compression garment worn for 4-6 weeks (reduces swelling, promotes skin retraction). Drain placement optional (depends on extent of dissection). Activity restriction: avoid heavy upper body exercise for 4-6 weeks. Follow-up: assess for hematoma, seroma, contour irregularities.

Complications

Hematoma: most common early complication; may require drainage. Seroma: aspiration; compression garment compliance. NAC depression/crater deformity: from excessive glandular excision directly beneath the NAC. Prevention: leave a 1 cm disc of tissue under the NAC.

Treatment: fat grafting. Contour irregularity: asymmetry, residual tissue, over-resection. NAC necrosis: rare; risk increases with circumareolar and skin-reducing approaches. Asymmetry: most common reason for revision.

Altered NAC sensation: usually temporary. Recurrence: rare if underlying cause addressed; may occur with persistent hormonal imbalance or resumption of offending drugs.

Clinical Pearls

Always perform a thorough medication review and endocrine workup before proceeding with surgery; treating the underlying cause may avoid surgery entirely. The combination of liposuction with direct glandular excision through a periareolar incision is the workhorse approach for most cases; liposuction alone is insufficient because the dense glandular tissue does not respond to suction. Leave a 1 cm cushion of tissue directly beneath the NAC to prevent the dreaded crater deformity; it is much easier to perform a minor revision for residual tissue than to correct a sunken NAC.

VASER (ultrasound-assisted) liposuction is particularly useful in gynecomastia because it can partially disrupt the fibrous glandular tissue, facilitating more complete removal and smoother contouring. In pubertal gynecomastia, counsel the patient and family that observation for 12-24 months is appropriate as most cases resolve spontaneously; surgery should not be offered prematurely. Always send excised tissue to pathology; male breast cancer accounts for 1% of all breast cancers and can present as gynecomastia.

References

• Rohrich RJ, Ha RY, Kenkel JM, Adams WP Jr. Classification and management of gynecomastia: defining the role of ultrasound-assisted liposuction. Plast Reconstr Surg. 2003;111(2):909-923.
• Simon BE, Hoffman S, Kahn S. Classification and surgical correction of gynecomastia. Plast Reconstr Surg. 1973;51(1):48-52.
• Braunstein GD. Gynecomastia. N Engl J Med. 1993;328(7):490-495.
• Handschin AE, Bietry D, Husler R, Banic A, Constantinescu MA. Surgical management of gynecomastia — a 10-year analysis. World J Surg. 2008;32(1):38-44.
• Johnson RE, Murad MH. Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin Proc. 2009;84(11):1010-1015.

Read this lecture as Markdown